![Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition) Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)](https://multimedia.elsevier.es/PublicationsMultimediaV1/file//23870206/0000015400000008/v1_202004190641/S2387020620301029/v1_202004190641/en/main.assets/gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNeMnx59J5MZq19QkIYapO3CcJ9CENpsFcm3MeAXF+MMxsJrl5MogwoNyiiPrWn5EolbGSaePAm7SObORQuBLnHrM7CHCTbkUMrraqmu9cvf1qcxz0uTdfKiScYAzZBdozn4RNxKvbrW1xfvj96Wx8aFuv5gLgcpBQnzBEHunHoxsilEuXZRoaDm7WdrsaQBmiuGI5lCZ4jflFZAD2nf1t0QJnzMMzv4L/Ix2pS6xV59L8TLJrVsDqnNYVGfxcAnMgk=)
Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)
![Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena](https://www.drugdevelopment-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/Drug%20development/Multiple%20myeloma.jpg)
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
![Cells | Free Full-Text | Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications Cells | Free Full-Text | Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications](https://www.mdpi.com/cells/cells-10-00336/article_deploy/html/images/cells-10-00336-g001.png)
Cells | Free Full-Text | Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
![Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost | International Journal of Hematology Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost | International Journal of Hematology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12185-020-02841-w/MediaObjects/12185_2020_2841_Fig1_HTML.png)
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost | International Journal of Hematology
![Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse](https://pub.mdpi-res.com/curroncol/curroncol-30-00179/article_deploy/html/images/curroncol-30-00179-g001.png?1676859747)
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
![Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet Oncology Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet Oncology](https://www.thelancet.com/cms/attachment/93bc7fd9-9da9-4386-a6c9-ec1dfbf5c438/gr1_lrg.gif)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet Oncology
![Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/4054c0bb-6add-4d79-a311-e460cd3357f2/gr1.gif)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Dr. Reddy's Laboratories Ltd. - Multiple myeloma is a cancer of plasma cells that generally affects people in the age group of 52-61 years and early diagnosis is possible with routine blood
![Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition) Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)](https://multimedia.elsevier.es/PublicationsMultimediaV1/file//23870206/0000015400000008/v1_202004190641/S2387020620301029/v1_202004190641/en/main.assets/gr2.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNeMnx59J5MZq19QkIYapO3CcJ9CENpsFcm3MeAXF+MMxsJrl5MogwoNyiiPrWn5EolbGSaePAm7SObORQuBLnHrM7CHCTbkUMrraqmu9cvf1qcxz0uTdfKiScYAzZBdozn4RNxKvbrW1xfvj96Wx8aFuv5gLgcpBQnzBEHunHoxsilEuXZRoaDm7WdrsaQBmiuGI5lCZ4jflFZAD2nf1t0QJnzMMzv4L/Ix2pS6xV59L8TLJrVsDqnNYVGfxcAnMgk=)